Sweden's Immunovia Q2 sales rise on PancreaSure test uptake

Immunovia AB (publ)

06/08/2026 07:40

Overview
Sweden diagnostic firm's Q2 net sales rose, driven by PancreaSure test uptake
Adjusted loss per share for Q2 improved yr/yr to -0.03 SEK
Company's Q2 cash burn rate was below guidance due to lower clinical study spending

Outlook
Company did not provide specific financial guidance for current or future periods

Result Drivers
TEST UPTAKE - Increased adoption of PancreaSure by high-risk surveillance centers in the U.S. drove Q2 sales, per CEO Jeff Borcherding
CLINICAL VALIDATION - High sensitivity and specificity data for PancreaSure in the Medicare population supported the company's Medicare coverage submission plans
LOWER CLINICAL STUDY SPENDING - Cash burn was below guidance due to reduced spending on clinical studies

Company press release: ID:nMFN76FxQL

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted Loss Per Share
 
SEK 0.03
 

Analyst Coverage
Wall Street's median 12-month price target for Immunovia AB (publ) is SEK0.42, about 130.8% above its August 5 closing price of SEK0.18

Reuters Recommended Reads
Aug 4 - Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage
Aug 4 - Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth
Aug 5 - Caris Life Sciences Q2 revenue rises 45% on the back of molecular profiling services

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)